Chronic Obstructive Pulmonary Disease antibodies

and ELISA kits, proteins related to Chronic Obstructive Pulmonary Disease.

Introduction to Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and progressive lung condition that obstructs airflow, making breathing increasingly difficult. As a leading cause of morbidity and mortality worldwide, COPD significantly impacts individuals’ quality of life and poses substantial healthcare challenges. Recent advancements in biomedical research have spotlighted the role of antibodies in understanding and combating COPD. Our landing page explores the latest breakthroughs in antibody-related studies, highlighting innovative therapies and potential treatments aimed at mitigating inflammation, enhancing immune response, and slowing disease progression. By delving into cutting-edge research on antibodies, we aim to shed light on promising strategies that offer hope for improved management and eventual alleviation of COPD. Join us in advancing the fight against this pervasive respiratory disease through targeted antibody research and development.

Chronic Obstructive Pulmonary Disease biomarkers

PA1080

Anti-VEGF/VEGFA Antibody Picoband®, The promotion of NA for the expression of CD31 and VEGF in vivo . (A 1 –A 3 ) Immunofluorescence staining indicating the CD31 expression in the healed skin...

PA1079

Anti-TNF alpha Antibody Picoband®, Immunomodulatory properties pathway of the hydrogel. (A, B) Flow cytometry analysis of the macrophage surface markers CD11C and CD86. (C) Representative ...

PA1352

Anti-Interleukin-6 IL6 Antibody Picoband®, Collagen deposition, inflammation, and angiogenesis analyses in acute large-area wounds. (A) Masson staining and immunofluorescence of IL-6 (red) and ...

Protein Name	Gene Name	Function
C-reactive Protein (CRP)	CRP	Acute phase protein involved in systemic inflammation
Interleukin-6 (IL-6)	IL6	Pro-inflammatory cytokine involved in immune response
Tumor Necrosis Factor-alpha (TNF-α)	TNF	Pro-inflammatory cytokine regulating immune cells
Surfactant Protein D (SP-D)	SFTPD	Modulates innate immune response in the lungs
Matrix Metalloproteinase-9 (MMP-9)	MMP9	Involved in extracellular matrix remodeling and inflammation
Fibronectin	FN1	Extracellular matrix protein involved in tissue repair and remodeling
Neutrophil Elastase	ELANE	Proteolytic enzyme contributing to inflammation and tissue damage
YKL-40	CHI3L1	Inflammatory marker associated with tissue remodeling
Soluble Receptor for Advanced Glycation End-products (sRAGE)	AGER	Modulates inflammatory responses in the lungs
Interleukin-1 beta (IL-1β)	IL1B	Pro-inflammatory cytokine involved in immune response
CC Chemokine Ligand 5 (CCL5)	CCL5	Attracts immune cells to sites of inflammation
Granulocyte-Colony Stimulating Factor (G-CSF)	CSF3	Stimulates production of white blood cells
Eotaxin	CCL11	Chemokine involved in eosinophil recruitment
Transforming Growth Factor-beta (TGF-β)	TGFB1	Regulates cell growth and differentiation, involved in fibrosis
Vascular Endothelial Growth Factor (VEGF)	VEGFA	Promotes blood vessel formation and permeability

Important Mechanisms

Inflammation and Immune Response in COPD

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent inflammation in the airways, lung tissue, and pulmonary blood vessels. This inflammatory response is primarily driven by exposure to noxious particles and gases, such as those found in cigarette smoke, which activate various immune cells including macrophages, neutrophils, and T-lymphocytes. These activated cells release pro-inflammatory cytokines, chemokines, and proteases, leading to tissue damage, airway remodeling, and obstruction. Understanding the intricate balance between pro-inflammatory and anti-inflammatory mechanisms is crucial for developing targeted therapies. Research in this sub-area focuses on identifying key inflammatory pathways and molecular targets that can be modulated to reduce chronic inflammation, preserve lung function, and improve patient outcomes. Additionally, exploring the role of innate and adaptive immunity in COPD progression provides insights into potential biomarkers for disease severity and therapeutic response.

Oxidative Stress and Antioxidant Defense in COPD

Oxidative stress plays a pivotal role in the pathogenesis of COPD by disrupting the balance between oxidants and antioxidants in the lungs. Chronic exposure to inhaled pollutants, such as cigarette smoke, introduces reactive oxygen species (ROS) that overwhelm the lung's antioxidant defenses, including enzymes like superoxide dismutase and glutathione peroxidase. This imbalance leads to cellular damage, apoptosis of structural cells, and exacerbation of inflammatory responses. Additionally, oxidative stress contributes to the modification of proteins, lipids, and DNA, further impairing lung function and accelerating disease progression. Research in this area aims to elucidate the sources and effects of oxidative stress in COPD, as well as to develop strategies to enhance antioxidant defenses. Potential therapeutic approaches include the use of antioxidant supplements, pharmacological agents that boost endogenous antioxidant systems, and interventions that reduce the production of ROS. By mitigating oxidative damage, it is possible to slow the progression of COPD and improve the quality of life for affected individuals.